Lateral Flow Immunoassay for Quantitative Small Analyte Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting prescription opioid abuse, nicotine metabolism, and heavy metal toxicity are either not suitable for point-of-care detection or are labor-intensive and expensive, lacking the ability to provide immediate, quantitative results at the site of sample collection.
Innovation Solution
A point-of-care assay using a non-competitive lateral flow immunoassay that employs binding agents and capture agents, such as antibodies and aptamers, to quantify small analytes like drugs, metabolites, hormones, and heavy metals in biological samples, allowing for simultaneous detection of multiple analytes and providing immediate results.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional laboratory methods (flame atomic absorption spectrometry, graphite furnace atomic absorption spectrometry, inductively coupled plasma-atomic emission spectroscopy, inductively coupled plasma mass spectrometry) are used to detect heavy metals and small analytes, then measurement precision and reliability are improved, but device complexity, loss of time, and productivity are worsened due to labor-intensive procedures, long processing times, and high costs
Solution Approach 1:
The patent extracts the essential detection function from complex laboratory instrumentation and implements it in a simplified point-of-care device. The lateral flow immunoassay format removes the need for expensive, time-consuming laboratory equipment while maintaining detection capability through antibody-antigen binding and fluorescent labeling.
Solution Approach 2:
The patent replaces mechanical/physical laboratory methods (atomic absorption, plasma spectroscopy) with a biochemical immunoassay system. This substitution uses biological molecules (antibodies, aptamers) and fluorescent detection instead of complex physical instrumentation, dramatically reducing time and complexity while maintaining precision.
2Measurement precision
If traditional laboratory methods are used for analyte detection, then measurement precision is improved, but device complexity and ease of operation are worsened due to requirement for specialized equipment and trained personnel
Solution Approach 1:
The lateral flow immunoassay is designed to be self-contained and self-explanatory. The device includes all necessary reagents (antibodies, fluorescent labels, buffer solutions) pre-loaded in the test strip, and the procedure follows automatic capillary flow without requiring skilled operators. Results are visually interpretable or readable with simple equipment.
Solution Approach 2:
The detection system is segmented into discrete functional zones on the test strip (sample application area, reaction zone with capture antibodies, detection zone with fluorescent particles). This segmentation allows each component to perform its specific function independently, simplifying the overall operation while maintaining detection precision.
3Measurement precision
If enzyme-mediated immunoassays are used for drug testing, then sensitivity is improved, but manufacturing precision and object-generated harmful factors are worsened due to cross-reactivity between drugs of the same class
Solution Approach 1:
The patent employs multiple different antibodies or aptamers, each with highly specific binding characteristics tailored to particular analytes. This local specialization of binding properties allows discrimination between structurally similar compounds, reducing cross-reactivity while maintaining sensitivity for each specific target.
Solution Approach 2:
The assay uses composite recognition systems combining antibodies with aptamers or using multi-epitope recognition. This composite approach enhances specificity by requiring multiple binding interactions for positive detection, reducing false positives from cross-reactivity while maintaining high sensitivity.
4Productivity
If quantitative detection methods are developed for point-of-care use, then productivity is improved by eliminating laboratory shipping and processing, but device complexity and manufacturing precision are worsened
Solution Approach 1:
The patent merges sample application, reagent mixing, incubation, separation, and detection functions into a single integrated lateral flow test strip. This consolidation eliminates the need for separate laboratory equipment and manual steps, improving productivity while keeping the device relatively simple through clever integration of multiple functions in one format.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables fast and accurate determination of analyte levels in biological samples at the point of collection, reducing the need for laboratory testing and providing immediate, quantitative results for healthcare providers and veterinary use.
Implementation Method 1
a binding agent and a capture agent that simultaneously bind the analyte in a sandwich assay
Implementation Method 2
non-competitive lateral flow immunoassay
Data Source
Figure 1A~1B
Figure 2A~2B
Figure 3A~3C
AI summary
Point-of-care assays for quantitatively measuring the amount of small analytes, such as opioids, tetrahydrocannibinol ("THC"), or hormones, in a biological sample are disclosed. The assays are capable of non-competitive detection of a small analyte using binding agents that selectively bind the analyte and capture agents that selectively bind a complex of the binding agent and analyte but do not bind either free binding agent or free analyte. The assay is capable of simultaneous diction of multiple analytes for multiplex analysis and quantitative control. Quantitative measurements are obtained by plotting results against a response surface calculated from a plurality of analyte standards and adjusted using internal controls.